Navigation Links
Dr. Paul Billings joins Trovagene's Scientific Advisory Board
Date:11/19/2012

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of transrenal molecular diagnostics, announced today that Dr. Paul Billings has joined the Company's Scientific Advisory Board. A board certified internist and clinical geneticist, Dr. Paul R. Billings currently serves as Chief Medical Officer at Life Technologies Corporation. Dr. Billings brings extensive expertise and clinical experience in the areas of genomics and molecular medicine.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"We are honored that Dr. Billings will be collaborating with Trovagene," states Antonius Schuh, Ph.D., chief executive officer of Trovagene. "He specializes in improving patient care through expanding the use of medically relevant genomic technologies in clinical settings," he continues, "and his expertise is critical he helps shape policy in the rapidly evolving field of genomic medicine."

Dr. Billings has had a distinguished career as a physician, business executive and researcher. He has authored nearly 200 publications and books on genomic medicine and currently serves on the Scientific Advisory Board of the Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs, and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Most recently, he served as Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. Previously, he was senior vice president for corporate development at Laboratory Corporation of America Holdings (LabCorp). He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine, including GeneSage Inc., Omicia, Inc. and CELLective Dx Corporation. Dr. Billings has held academic appointments at Harvard Medical School, Stanford School of Medicine and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.  Trovagene is leveraging its intellectual property in oncogene mutations via out-licensing and use of its transrenal technologies to extend oncogene mutation detection using urine as a sample.  As a non-invasive and abundant sample, urine may overcome many of the cost and collection challenges associated with biopsy, as well as the volume limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in chronic lymphocytic leukemia (CLL) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact

Trovagene, Inc.    
Charlie Rodi                   
Vice President and Chief Scientific Officer
+1 (858) 952-7670                       
crodi@trovagene.com              
www.trovagene.com                     

 

 

 


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nutrilys Del Mar Joins Health Forces With LAPD Underwater Dive Unit
2. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
3. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
4. Effie Toshav Joins Fenwick - Broadens Life Sciences Service Platform
5. David F. Harty Joins Systech International as Vice President
6. Jim DuCharme Joins Prime Therapeutics as Chief Financial Officer
7. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
8. Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
9. Anthony Creed Joins DDSTUDIO As GM, Experience Design
10. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
11. American Society of Hematology joins European Hematology Association, Patient Groups in Issuing International Call to Action to Alleviate Drug Shortages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... NORTH CHICAGO, Ill. , March 23, 2017 /PRNewswire/ ... actress, dancer and Emmy Award-winning choreographer Julianne Hough ... a campaign called "Get in the Know about ME ... AbbVie, is dedicated to inspiring women to learn about ... in 10 women, 1 and to address their ...
(Date:3/23/2017)... , March 23, 2017 ... presented in Brussels , My ... change bad sun habits into life-saving ones, was ... Association (AIM). Launched in 2016, the "Nudging for ... it easy and desirable for people to change ...
(Date:3/22/2017)... Mar. 22, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 10.9% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare ... Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, ... for all medical chart types with a comprehensive set of features including built-in ...
(Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider ... protein expression in circulating tumor cells using microfluidic western blotting” in Nature Communications ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
Breaking Medicine News(10 mins):